Evidence map›Paper›PMID 37599324›Full record

GuidelineInternational journal of clinical oncology2023

Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with DNA mismatch repair deficient (dMMR) tumors, third edition.

Saori Mishima, Yoichi Naito, Kiwamu Akagi, Naomi Hayashi, Akira Hirasawa, Tomoro Hishiki, Ataru Igarashi, Masafumi Ikeda, Shigenori Kadowaki, Hiroaki Kajiyama and 22 more

Open access · hybridAbstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in International journal of clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 20 institutions in 1 country.

Saori MishimaNational Cancer Center Hospital East, Kashiwa, Japan.ORCID http://orcid.org/0000-0002-5922-1487
Yoichi NaitoNational Cancer Center Hospital East, Kashiwa, Japan.
Kiwamu AkagiSaitama Cancer Center, Saitama, Japan.
Naomi HayashiThe Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Akira HirasawaOkayama University, Okayama, Japan.
Tomoro HishikiChiba University, Chiba, Japan.
Ataru IgarashiYokohama City University School of Medicine, Yokohama, Japan.
Masafumi IkedaNational Cancer Center Hospital East, Kashiwa, Japan.
Shigenori KadowakiAichi Cancer Center, Aichi, Japan.
Hiroaki KajiyamaNagoya University, Aichi, Japan.
Motohiro KatoThe University of Tokyo, Tokyo, Japan.
Hirotsugu KenmotsuShizuoka Cancer Center, Shizuoka, Japan.
Yasuhiro KoderaNagoya University Hospital, Aichi, Japan.
Keigo KomineTohoku University, Miyagi, Japan.
Takafumi KoyamaNational Cancer Center Hospital, Tokyo, Japan.
Osamu MaedaNagoya University Hospital, Aichi, Japan.
Mitsuru MiyachiKyoto Prefectural University of Medicine, Kyoto, Japan.
Hiroshi NishiharaKeio University, Tokyo, Japan.
Hiroyuki NishiyamaTsukuba University, Ibaraki, Japan.
Shouichi OhgaKyushu University, Fukuoka, Japan.
Wataru OkamotoHiroshima University Hospital, Hiroshima, Japan.
Eiji OkiKyushu University, Fukuoka, Japan.
Shigeru OnoJichi Medical University, Tochigi, Japan.
Masashi SanadaNational Hospital Organization Nagoya Medical Center, Aichi, Japan.
Ikuo SekineTsukuba University, Ibaraki, Japan.
Tadao TakanoTohoku University, Miyagi, Japan.
Kayoko TaoNational Cancer Center Hospital, Tokyo, Japan.
Keita TerashimaNational Center for Child Health and Development, Tokyo, Japan.
Katsuya TsuchiharaNational Cancer Center Hospital East, Kashiwa, Japan.
Yasushi YatabeNational Cancer Center Hospital, Tokyo, Japan.
Takayuki YoshinoNational Cancer Center Hospital East, Kashiwa, Japan.
Eishi BabaKyushu University, Fukuoka, Japan. pj.ca.u-uhsuyk.m@988.ihsie.abab.
National Cancer Center Hospital East · JPKyushu University · JPTokyo National Hospital · JPNagoya University Hospital · JPTohoku University · JPAichi Cancer Center · JPChiba University · JPHiroshima University Hospital · JPJichi Medical University · JPKeio University · JPKyoto Prefectural University of Medicine · JPNagoya University · JPNational Center For Child Health and Development · JPNational Hospital Organization · JPOkayama University · JPSaitama Cancer Center · JPShizuoka Cancer Center · JPThe Cancer Institute Hospital · JPThe University of Tokyo · JPYokohama City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundClinical trials have reported the efficacy of immune checkpoint inhibitors in the treatment of mismatch repair-deficient (dMMR) advanced solid tumors. The accumulated evidence of tumor agnostic agent has been made since PD-1 inhibitor was approved and used in clinical practice. Therefore, we have revised the guideline "Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition".

methodsClinical questions regarding medical care were formulated for patients with dMMR advanced solid tumors. Relevant publications were searched by PubMed and Cochrane Database. Critical publications and conference reports were added manually. Systematic reviews were performed for each clinical question for the purpose of developing clinical recommendations. The committee members identified by Japan Society of Clinical Oncology (JSCO), Japanese Society of Medical Oncology (JSMO), and Japanese society of pediatric hematology/oncology (JSPHO) voted to determine the level of each recommendation considering the strength of evidence, expected risks and benefits to patients, and other related factors. Thereafter, a peer review by experts nominated from JSCO, JSMO, and JSPHO and the public comments among all societies' members were done.

resultsThe current guideline describes two clinical questions and eight recommendations for whom, when, and how MMR status should be tested.

conclusionIn this guideline, the committee proposed eight recommendations for performing MMR testing properly to select patients who are likely to benefit from immunotherapy.

Indexed as

Colorectal NeoplasmsHematologyNeoplasmsDNA Mismatch RepairHumansImmunotherapyJapanMedical OncologyAdvanced solid tumorClinical practice guidelineImmunotherapyMicrosatellite instability-high (MSI-H)Mismatch repair-deficient (dMMR)PD-1/PD-L1 inhibitor

Identifiers

PMID37599324
PMCPMC10542286
OpenAlexW4386011348

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.